Sensitive Detection of SARS-CoV-2–Specific Antibodies in Dried Blood Spot Samples
Gabriella L. Morley, Stephen Taylor, Sian Jossi, Marisol Perez-Toledo, Sian E. Faustini, Edith Marcial-Juarez, Adrian M. Shields, Margaret Goodall, Joel D. Allen, Yasunori Watanabe, Maddy L. Newby, Max Crispin, Mark T. Drayson, Adam F. Cunningham, Alex G. Richter
1, and Matthew K. O’Shea
1
Author affiliations: University of Birmingham, Birmingham, UK (G.L. Morley, S. Taylor, S. Jossi, M. Perez-Toledo, S.E. Faustini, E. Marcial-Juarez, A.M. Shields, M. Goodall, M.T. Drayson, A.F. Cunningham, A.G. Richter, M.K. O’Shea); The Saving Lives Charity, Birmingham (S. Taylor); University Hospitals Birmingham NHS Foundation Trust, Birmingham (S. Taylor, A.M. Shields, A.G. Richter, M.K. O’Shea); University of Southampton, Southampton, UK (J.D. Allen, Y. Watanabe, M.L. Newby, M. Crispin); University of Oxford, Oxford, UK (Y. Watanabe)
Main Article
Figure 2
Figure 2. Effectiveness of DBS sampling for SARS-CoV-2 anti-spike glycoprotein detection. A) Correlation between matched DBS eluate (1:10) and serum (1:100) OD450 ELISA results (n = 87). Red circles indicate PCR-positive samples (n = 31). Black circles indicate PCR-unknown samples (n = 56). B) Bland-Altman mean-difference comparison of DBS eluate (1:10) and serum (1:100) OD450 ELISA results (dashed lines indicate 95% limits of agreement [−0.281 to 0.504]). DBS, dried blood spot; OD450, optical density at 450 nm; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Main Article
Page created: September 11, 2020
Page updated: November 19, 2020
Page reviewed: November 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.